Journey Strategic Wealth LLC Has $1.19 Billion Stock Position in Johnson & Johnson (NYSE:JNJ)

Journey Strategic Wealth LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,174,646 shares of the company's stock after buying an additional 135,788 shares during the period. Johnson & Johnson accounts for approximately 41.5% of Journey Strategic Wealth LLC's holdings, making the stock its biggest holding. Journey Strategic Wealth LLC owned about 0.30% of Johnson & Johnson worth $1,189,843,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $26,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Finally, von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $1.27 during mid-day trading on Friday, hitting $168.29. 6,199,690 shares of the stock were exchanged, compared to its average volume of 8,375,731. The stock's fifty day simple moving average is $156.08 and its two-hundred day simple moving average is $155.78. The stock has a market capitalization of $404.92 billion, a price-to-earnings ratio of 18.00, a P/E/G ratio of 2.16 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the company posted $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Raymond James Financial dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Finally, UBS Group lifted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.